# Ata Prolactinoma Axis Reassess

> Recommends reassessing all pituitary axes in patients with macroprolactinoma and central hypogonadism who have had successful dopamine agonist treatment. Use when managing a macroprolactinoma patient after dopamine agonist treatment with normalized prolactin and tumor shrinkage.

- Skill: `dromlakhani/ata-prolactinoma-axis-reassess` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/ata-prolactinoma-axis-reassess`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/ata-prolactinoma-axis-reassess/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/ata-prolactinoma-axis-reassess

---


# Reassess pituitary axes after dopamine agonist treatment in macroprolactinoma

## STEP 1 — Gather Information
Confirm macroprolactinoma diagnosis (MRI >10mm), central hypogonadism (low testosterone/E2 with inappropriately low LH/FSH), and successful dopamine agonist treatment (normoprolactinemia, tumor shrinkage ≥30%, symptom improvement). Collect baseline pituitary hormones (cortisol, fT4, TSH, IGF-1, gonadotropins, sex steroids) and current symptoms.

## STEP 2 — Rule In / Rule Out
Is there evidence of successful dopamine agonist treatment? If yes, proceed to axis reassessment; if no, optimize dopamine agonist dose or consider surgery/radiation before reassessment.

## STEP 3 — Classify or Stratify
Assess each pituitary axis: adrenal (AM cortisol or ACTH stim), thyroid (fT4/TSH), gonadal (testosterone/E2, LH/FSH), GH (IGF-1), and DI (serum/urine osmolarity if polyuria). Classify each as sufficient, borderline, or deficient based on age-adjusted reference ranges.

## STEP 4 — Decide
For any deficient axis, initiate appropriate hormone replacement per endocrine guidelines; for borderline, repeat testing in 3-6 months; for sufficient, continue surveillance with annual clinical review and pituitary MRI.

## Clinical Guardrails / Mimics / Pitfalls
Do not assume normalization of prolactin implies recovery of other axes; do not discontinue dopamine agonist without confirming tumor stability; avoid empiric hormone replacement without biochemical confirmation; consider macroprolactinoma regrowth if symptoms worsen despite biochemical control.

## Concrete Clinical Example
A 42-year-old man with macroprolactinoma (12mm) and central hypogonadism (testosterone 150 ng/dL, LH 1.2 IU/L) achieved normoprolactinemia (<20 ng/mL) and 50% tumor shrinkage after 6 months of cabergoline. Reassessment revealed low IGF-1 (80 ng/mL) and low testosterone (120 ng/dL); he started testosterone gel and GH replacement.

**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118